CVKD (Cadrenal Therapeutics) Total Assets: $2.86 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CVKD Cadrenal Therapeutics Inc CVKD
30 GF Score
Price $2.03
! 2 Warning Signs
View Full Analysis

What is Cadrenal Therapeutics Total Assets?

Cadrenal Therapeutics CVKD +2.01% 30 Total Assets is $2.86 Mil as of Mar. 2026. GuruFocus rates CVKD with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Cadrenal Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $2.86 Mil.

During the past 12 months, Cadrenal Therapeutics's average Total Assets Growth Rate was 200.90% per year. During the past 3 years, the average Total Assets Growth Rate was -24.60% per year.

During the past 4 years, Cadrenal Therapeutics's highest 3-Year average Total Assets Growth Rate was -24.60%. The lowest was -24.60%. And the median was -24.60%.

Total Assets is connected with ROA %. Cadrenal Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -277.87%. Total Assets is also linked to Revenue through Asset Turnover. Cadrenal Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Cadrenal Therapeutics  (NAS:CVKD) Total Assets Explanation

Total Assets is connected with ROA %.

Cadrenal Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-9.988/( (4.327+2.862)/ 2 )
=-9.988/3.5945
=-277.87 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cadrenal Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (4.327+2.862)/ 2 )
=0/3.5945
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cadrenal Therapeutics Total Assets Related Terms

Cadrenal Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Cadrenal Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cadrenal Therapeutics Total Assets Chart

Cadrenal Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Assets
0.78 8.52 10.12 4.33

Cadrenal Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.95 5.98 4.09 4.33 2.86
CVKD
30GF Score
Cadrenal Therapeutics Inc CVKD
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cadrenal Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cadrenal Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=2.739+1.588
=4.33

Cadrenal Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=1.797+1.065
=2.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $2.86 Mil mean?
Cadrenal Therapeutics (CVKD) has a Total Assets of $2.86 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Cadrenal Therapeutics and its competitors.
Is Cadrenal Therapeutics' Total Assets too high?
Cadrenal Therapeutics' current Total Assets is $2.86 Mil. Overall, Cadrenal Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cadrenal Therapeutics' Total Assets compare to RVPH and IMNN?
Cadrenal Therapeutics' Total Assets of $2.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Cadrenal Therapeutics and its competitors. Cadrenal Therapeutics's current Total Assets is $2.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cadrenal Therapeutics stock overvalued right now?
Cadrenal Therapeutics (CVKD) has a current Total Assets of $2.86 Mil. The current Total Assets is $2.86 Mil. Cadrenal Therapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Cadrenal Therapeutics (CVKD), the current Total Assets is $2.86 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cadrenal Therapeutics Business Description

Address 822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
30GF Score

Get the complete analysis for CVKD

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.03
Price